Although RAP's commercialization has been agonizingly slow - I...

Although RAP's commercialization has been agonizingly slow - I think the big negative news is behind us. I just cant see how a company sitting on IP who has worked with or working with the following companies/organizations will amount to nothing;

Hospitals
- NHS (ongoing)
- Health Hub Doctors Morayfield (Queensland Health)
- Sana Linkum Lichtenberg
- Massachusetts General
- Texas Childrens Hospital
- Curtin

Telehealth
- Phenix
- WMA
- Medgate
- Health Engine
- Coviu
- Ilara

Charities
- Medecins Sans Frontieres
- Bill and Melinda Gates Foundation
- Diabetes Queensland

Pharma
- Sanofi
- RB
- AstraZeneca


Other
- DARPA / Lockhead Martin
- Creosphere
- University of Queensland

Obviously, some of those have worked out better than others, but most are still bubbling along in some respect. These are just the ones we know of.

I think we are still a way away from booking some serious revenue and probably over a year until we get back into the 20c range as it appears many long term hot copperites have given up (not so much the biggest investors).

What im looking forward to is;

- FDA approval of sleepcheck
- FDA approval of ResAppDx (after we have real-world data)
- Further European telehealth deals
- Asian (specifically Singapore) telehealth deal
- Results of Ilara study and in-clinic adoption
- NHS study results and use of the device in a clinical setting (probably not revenue-generating initially)
- Integration of ResAppDX with Health Direct (the best candidate for significant revenue short term)
- Paid use of ResAppDX in respiratory clinics
- COPD results and commercialization
- Further collaboration with clinical studies with the 'cough counter product'
- WMA launch an revenue generation
- RB direct to consumer product launch (the big unknown and given the zero sp action has not been factored into the share price)

It's evident this company can attract interest from numerous health organisations and when the revenue comes, it will unlock all of the phase 2 products which are pipe dreams currently.

Yeah, they have stuffed things up and communication often lacks frequency and detail, but there is proof that the product is real and sort after. This type of technology is the future, and outside of the established tech-oligarchs, it could be argued that RAP is in a pretty solid position and only valued at $70 million.